SLNO · As filed with the SEC
Soleno Therapeutics balance sheet, by fiscal year
The statement as Soleno Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Balance Sheets · USD
| USD | FY2025 Dec 31, 2025 | FY2024 Dec 31, 2024 | FY2023 Dec 31, 2023 | FY2022 Dec 31, 2022 |
|---|---|---|---|---|
| Assets | ||||
| Current assets | ||||
| Cash and cash equivalents | 70,106,000 | 87,928,000 | 169,681,000 | 14,602,000 |
| Marketable securities | 235,366,000 | 203,509,000 | — | — |
| Accounts receivable, net | 28,208,000 | — | — | — |
| Inventory, net | 15,024,000 | — | — | — |
| Prepaid expenses and other current assets | 7,110,000 | 2,452,000 | 1,677,000 | 1,045,000 |
| Total current assets | 355,814,000 | 293,889,000 | 171,358,000 | 15,647,000 |
| Long-term assets | ||||
| Property and equipment, net | 185,000 | 186,000 | 12,000 | 26,000 |
| Operating lease right-of-use assets | 2,191,000 | 2,798,000 | 407,000 | 131,000 |
| Intangible assets, net | 4,861,000 | 6,805,000 | 8,749,000 | 10,693,000 |
| Long-term marketable securities | 200,616,000 | 27,211,000 | — | — |
| Other long-term assets | 163,000 | 83,000 | 165,000 | — |
| Total assets | 563,830,000 | 330,972,000 | 180,691,000 | 26,497,000 |
| Liabilities and stockholders’ equity | ||||
| Current liabilities | ||||
| Accounts payable | 12,435,000 | 8,882,000 | 3,149,000 | 1,777,000 |
| Accrued compensation | 9,677,000 | 4,776,000 | 3,135,000 | 1,675,000 |
| Accrued clinical trial site costs | — | 1,826,000 | 3,393,000 | 3,222,000 |
| Operating lease liabilities | 726,000 | 526,000 | 273,000 | 155,000 |
| Contingent liability for Essentialis purchase price | 20,327,000 | — | — | — |
| Other current liabilities | 18,198,000 | 2,737,000 | 1,555,000 | 484,000 |
| Total current liabilities | 61,363,000 | 18,747,000 | 11,505,000 | 7,313,000 |
| Long-term liabilities | ||||
| 2018 PIPE Warrants | — | — | 0 | 1,000 |
| Contingent liability for Essentialis purchase price | — | 14,791,000 | 11,549,000 | 8,835,000 |
| Long-term debt, net | 49,863,000 | 49,828,000 | — | — |
| Long-term lease liabilities | 1,964,000 | 2,472,000 | 130,000 | 0 |
| Other long-term liabilities | 525,000 | 21,000 | — | — |
| Total liabilities | 113,715,000 | 85,859,000 | 23,184,000 | 16,149,000 |
| Stockholders’ equity | ||||
| Common stock, $0.001 par value, 100,000,000 shares authorized, 52,286,881 and 45,703,811 shares issued and outstanding at December 31, 2025 and 2024, respectively | 52,000 | 46,000 | 32,000 | 8,000 |
| Additional paid-in-capital | 881,018,000 | 696,966,000 | 433,885,000 | 247,762,000 |
| Accumulated other comprehensive income | 415,000 | 361,000 | — | — |
| Accumulated deficit | (431,370,000) | (452,260,000) | (276,410,000) | (237,422,000) |
| Total stockholders' equity | 450,115,000 | 245,113,000 | 157,507,000 | 10,348,000 |
| Total liabilities and stockholders'equity | 563,830,000 | 330,972,000 | 180,691,000 | 26,497,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.